Clearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based Drink
June 11, 2024 07:44 ET | Clearmind Medicine Inc.
Vancouver, Canada, June 11, 2024 (GLOBE NEWSWIRE) --  Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and...
Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial
March 13, 2024 08:14 ET | Clearmind Medicine Inc.
Vancouver, Canada, March 13, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a clinical- stage biotech company focused on discovery...
MAPS Announces Celestial Plans for Its 38th Anniversary MAPS, which celebrates its 38th anniversary on April 8, will celebrate with a total solar eclipse at the Texas Eclipse 2024 festival in Texas
Societal Color Logo and Tagline.png
Societal CDMO and Benuvia Sign Co-Marketing Agreement Designed to Promote Complementary CDMO and API Manufacturing Services to Drug Developers
February 01, 2024 07:00 ET | Societal CDMO, Inc.
Agreement Broadly Applicable to All Therapeutic Areas with Specific Focus on the Growing Psychedelic and Cannabinoid Drug Development Markets Complementary Capabilities Range from API Manufacturing...
MAPS Unveils Improved Fiscal Sponsorship Program, Empowering Innovators in the Psychedelic Movement To date, MAPS has supported nearly 70 organizations worldwide to advance charitable projects in the psychedelic movementCurrently, MAPS serves as a fiscal sponsor for 10 organizations in the newly...
MAPS Welcomes New Investors, Name Change for MAPS Public Benefit Corporation MAPS shares ownership of Lykos with mission-aligned investors, will continue to advance psychedelic research, change drug policy, and shape culture
MAPS Celebrates Submission of New Drug Application to FDA for MDMA-Assisted Therapy for PTSD The first NDA submission for any psychedelic-assisted therapy has been submitted through a 30-year effort initiated and led by the nonprofit MAPS
49ers’ Jon Feliciano supports MAPS as part of the 2023 NFL “My Cleats, My Cause” campaign MAPS was featured on custom-designed cleats worn by Offensive Lineman Jon Feliciano during the San Francisco 49ers vs Philadelphia Eagles game
SciSparc Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic-Based Treatment
November 28, 2023 08:25 ET | SciSparc Ltd
The pre- clinical trial conducted using the combined treatment of SciSparc's proprietary CannAmide™ and Clearmind Medicine's MEAI molecule TEL AVIV, Israel, Nov. 28, 2023 (GLOBE NEWSWIRE) -- ...
Federal Court of Australia Approves Incannex’s Re-Domiciliation and Lodgement of Court Orders With ASIC
November 16, 2023 08:30 ET | Incannex Healthcare
MELBOURNE, Australia, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (ASX: IHL) (NASDAQ: IXHL) (the “Company” or “Incannex”) is pleased to announce that the Federal Court of Australia...